These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 17339201

  • 21. The role of a low erythropoietin level for the polycythemia vera diagnosis.
    Lupak O, Han X, Xie P, Mahmood S, Mohammed H, Donthireddy V.
    Blood Cells Mol Dis; 2020 Feb; 80():102355. PubMed ID: 31525610
    [Abstract] [Full Text] [Related]

  • 22. Plasma erythropoietin in polycythemia.
    Erslev AJ, Caro J, Kansu E, Miller O, Cobbs E.
    Am J Med; 1979 Feb; 66(2):243-7. PubMed ID: 425968
    [Abstract] [Full Text] [Related]

  • 23. [Polycytaemia vera].
    Ugo V.
    Rev Prat; 2009 Nov 20; 59(9):1285-6. PubMed ID: 19961090
    [No Abstract] [Full Text] [Related]

  • 24. Congenital JAK2V617F polycythemia vera: where does the genotype-phenotype diversity end?
    Kelly K, McMahon C, Langabeer S, Eliwan H, O'Marcaigh A, Smith OP.
    Blood; 2008 Nov 15; 112(10):4356-7. PubMed ID: 18988882
    [No Abstract] [Full Text] [Related]

  • 25. Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis.
    Cazzola M.
    Haematologica; 2007 Dec 15; 92(12):1585-9. PubMed ID: 18055979
    [No Abstract] [Full Text] [Related]

  • 26. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
    Roda P, Ferrari A, Tang X, Erlich P, Eisenhower C, Patel MD, Irvin-Barnwell EA.
    Ann Hematol; 2014 Sep 15; 93(9):1467-72. PubMed ID: 24687383
    [Abstract] [Full Text] [Related]

  • 27. An evaluation of serum erythropoietin estimation by a hemagglutination inhibition assay in the differential diagnosis of polycythemia.
    Gibson J, Yuen E, Rickard KA, Kronenberg H.
    Pathology; 1984 Apr 15; 16(2):155-6. PubMed ID: 6462779
    [Abstract] [Full Text] [Related]

  • 28. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Santos FD, Duval A, Maynadié M, Hermouet S.
    Haematologica; 2008 Nov 15; 93(11):1723-7. PubMed ID: 18728027
    [Abstract] [Full Text] [Related]

  • 29. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.
    Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N, Lecron JC, Binquet C, Barro C, Hermouet S, Praloran V.
    Haematologica; 2004 Oct 15; 89(10):1194-8. PubMed ID: 15477203
    [Abstract] [Full Text] [Related]

  • 30. The JAK2 exon 12 mutations: a comprehensive review.
    Scott LM.
    Am J Hematol; 2011 Aug 15; 86(8):668-76. PubMed ID: 21674578
    [Abstract] [Full Text] [Related]

  • 31. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
    Verstovsek S, Silver RT, Cross NC, Tefferi A.
    Leukemia; 2006 Nov 15; 20(11):2067. PubMed ID: 16990780
    [No Abstract] [Full Text] [Related]

  • 32. Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis.
    Chen CC, Chen JL, Lin AJ, Yu LH, Hou HA.
    Ann Hematol; 2024 Jun 15; 103(6):1947-1965. PubMed ID: 38652240
    [Abstract] [Full Text] [Related]

  • 33. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
    Percy MJ, Scott LM, Erber WN, Harrison CN, Reilly JT, Jones FG, Green AR, McMullin MF.
    Haematologica; 2007 Dec 15; 92(12):1607-14. PubMed ID: 18055983
    [Abstract] [Full Text] [Related]

  • 34. Straightforward identification of masked polycythemia vera based on proposed revision of World Health Organization diagnostic criteria for BCR-ABL1-negative myeloproliferative neoplasms.
    Chu D, Cho YU, Jang S, Seo EJ, Park CJ.
    Ann Lab Med; 2015 Nov 15; 35(6):651-3. PubMed ID: 26354357
    [No Abstract] [Full Text] [Related]

  • 35. Serum erythropoietin concentration as a diagnostic tool for polycythemia vera.
    Cazzola M.
    Haematologica; 2004 Oct 15; 89(10):1159-60. PubMed ID: 15477197
    [No Abstract] [Full Text] [Related]

  • 36. Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera.
    Lanikova L, Babosova O, Swierczek S, Wang L, Wheeler DA, Divoky V, Korinek V, Prchal JT.
    Blood; 2016 Nov 03; 128(18):2266-2270. PubMed ID: 27647865
    [No Abstract] [Full Text] [Related]

  • 37. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment.
    Birgegård G, Wide L.
    Br J Haematol; 1992 Aug 03; 81(4):603-6. PubMed ID: 1390249
    [Abstract] [Full Text] [Related]

  • 38. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V, Misurin AV, Michiels JJ, Rozenberg JM, Sokolova MA, Ivanova VL, Kolosheinova TI, Manakova TE, Levina AA, Semenova EA, Khoroshko ND.
    Hematology; 2007 Dec 03; 12(6):473-9. PubMed ID: 17852451
    [Abstract] [Full Text] [Related]

  • 39. Updated threshold, renewed problems: should the diagnostic criteria of polycythemia vera be reconsidered? A retrospective cross-sectional cohort study.
    Uçan A, Özgeyik MO.
    Rev Assoc Med Bras (1992); 2024 Dec 03; 70(1):e20230497. PubMed ID: 38511749
    [Abstract] [Full Text] [Related]

  • 40. In situ detection of JAK2V617F within viable hematopoietic cells using gold nanoparticle technology.
    Sozer S, Aptullahoglu E, Shivarov V, Yavuz AS.
    Int J Lab Hematol; 2019 Aug 03; 41(4):e95-e98. PubMed ID: 30825256
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.